VP, New Ventures & Asset Creation

RTW Investments; New York (NY); On-site; USD 383,000 - 468,000; Full time

Benefits offered by this job

Healthcare concierge service

FSA/HSA plans

401(k) plan with company match

Employee Assistance Program (EAP)

Wellbeing benefit (Gympass)

Job summary

RTW Investments, LP in New York seeks a Vice President–New Ventures, Asset Selection to lead identification and evaluation of opportunities for company creation in biopharma and medical technologies. You will develop investment theses and build NewCos with strong PnL potential.

The role reports to the Managing Director, New Ventures, and requires deep life sciences knowledge, a track record in biotech investing, and readiness to travel up to 15%.

Qualifications

• Bachelor’s degree required; advanced degree (MD/PhD) strongly preferred.
• 5+ years in biotech/pharmaceutical investing, buy-side preferred.
• MD/PhDs with <5 years’ experience considered for switch.

Responsibilities

• Source and maintain pipeline of novel drug development ideas for NewCos.
• Conduct proprietary research across science, disease, commercial, IP, CMC, clin dev, regulatory, and valuation.
• Write, pitch, and maintain investment notes for company ideas.
• Build pitch decks including deal terms, clinical development, and financing.
• Develop expertise within therapeutic areas of coverage.
• Attend medical, banking and partnering conferences.
• Convert ideas into NewCos with PnL impact.

Skills

Biological sciences understanding

Independent work

Investor mindset

Strong communication

New ventures analysis

Education

Bachelor’s degree

MD or PhD

Job description

RTW Investments, LP in New York seeks a Vice President–New Ventures, Asset Selection to lead identification and evaluation of opportunities for company creation in biopharma and medical technologies. You will develop investment theses and build NewCos with strong PnL potential.

The role reports to the Managing Director, New Ventures, and requires deep life sciences knowledge, a track record in biotech investing, and readiness to travel up to 15%.